Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Widaplik
- Development stage
- Approved
- Lead developer
- George Medicines
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Widaplik (formerly GMRx2) is an FDA-approved, once-daily, single-pill triple combination therapy developed by George Medicines for the treatment of hypertension, including as an initial therapy. It contains low doses of three established antihypertensive agents: telmisartan (an angiotensin II receptor blocker), amlodipine (a calcium channel blocker), and indapamide (a thiazide-like diuretic). By targeting three distinct physiological pathways of blood pressure regulation, Widaplik provides rapid and effective blood pressure control with a favorable safety and tolerability profile. In addition to hypertension, Widaplik has been evaluated in the Phase III TRIDENT trial for the secondary prevention of recurrent stroke in patients with a history of intracerebral hemorrhage, demonstrating a significant 39% reduction in recurrent stroke risk.
- Brand names
- Widaplik
- Other names
- low-dose triple combination antihypertensive pilltelmisartan + amlodipine + indapamidetriple combination antihypertensive pilltriple single-pill combination
02
Targets
SLC12A3 (Thiazide-sensitive sodium-chloride cotransporter)AGTR1 (Angiotensin II Type-1 receptor)CACNA1C (Voltage-dependent L-type calcium channel subunit alpha-1C)
Beyond the preview
Go deeper on Widaplik.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Widaplik.